CHINA BLUECHEM (03983): Proposed appointment of Sun Yuduo as executive director
CHINA BLUECHEM (03983) announced that the Board proposed to appoint Mr. Sun Yuduo as an executive director. His term will commence from the date on which the Company's shareholders approve his appointment at the extraordinary general meeting of the Company to be held, and will last until the shareholders approve the appointment of a new session of directors at the Company's 2026 annual general meeting. The appointment of Mr. Sun as an executive director is subject to the approval of the shareholders at the extraordinary general meeting before it can take effect.
CHINA BLUECHEM (03983) announced that the board recommends the appointment of Mr. Sun Yuduo as an executive director. His term will commence from the date on which his appointment is approved by the shareholders of the Company at the extraordinary general meeting of the Company to be convened, and will last until the shareholders approve the appointment of a new session of directors at the 2026 annual general meeting of the Company. The appointment of Mr. Sun as an executive director is subject to approval by the shareholders at the extraordinary general meeting before it takes effect.
Mr. Kuang Xiaobing and Ms. Wu Xiuwei have resigned as joint company secretaries of the Company due to other work arrangements, with effect from October 27, 2026.
Pursuant to Rules 3.28 and 8.17 of the Listing Rules, Ms. Huang Zhi'ai has been appointed as the company secretary of the Company, with effect from October 27, 2026.
Following Mr. Kuang's resignation as the company secretary of the Company, he ceased to act as the authorized representative of the Company under Rule 3.05 of the Listing Rules, and Ms. Huang has been appointed as the authorized representative, with effect from October 27, 2026.
Related Articles

SUNAC SERVICES (01516) repurchased 300,000 shares on October 27 for approximately HK$206,600.

CHINARES PHARMA (03320): China Resources Double-Crane Pharmaceutical's net profit for the first three quarters was approximately RMB1.307 billion, a year-on-year decrease of 6.51%.

BASICSEMI (09971) repurchased 20,000 shares for HK$658,900 on October 27.
SUNAC SERVICES (01516) repurchased 300,000 shares on October 27 for approximately HK$206,600.

CHINARES PHARMA (03320): China Resources Double-Crane Pharmaceutical's net profit for the first three quarters was approximately RMB1.307 billion, a year-on-year decrease of 6.51%.

BASICSEMI (09971) repurchased 20,000 shares for HK$658,900 on October 27.






